Year: 2011
Type: review
Abstract: Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.
Source: Parasite
Institutions: Centre National de la Recherche Scientifique, Unité de Catalyse et Chimie du Solide, Université Lille Nord de France, Mahidol University, University of Oxford, Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit, Sanofi (France), Inserm, Institut Pasteur de Lille, Center for Infection and Immunity of Lille
Language: Spanish
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,695
OpenAlex ID: W2021547498
